Neurocrine Biosciences Inc 's ability to collect accounts receivable sequentially worsen to 4.4, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Neurocrine Biosciences Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 83 days, from 82 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 185 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1474, from overall ranking in the first quarter 2026 at 2729.

What is Receivable Turnover Ratio?
What is Neurocrine Biosciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NBIX Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	48.9 %	48.86 %	43.35 %	51.32 %	27.23 %
Y / Y Revenue Change	39.49 %	42.25 %	28.33 %	27.78 %	16.49 %
Receivable Turnover Ratio (TTM)	4.4	4.47	4.53	4.63	4.85
NBIX's Total Ranking	# 1474	# 2729	# 1350	# 352	# 921
Accounts Receivable average collection period days	83	82	81	79	75
Seq. Receivable Change	15.48 %	11.84 %	-5.66 %	22.21 %	15.45 %
Seq. Revenue Change	17.74 %	1.12 %	1.33 %	15.62 %	20.07 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 11
Healthcare Sector	# 186
Overall Market	# 1474

Receivable Turnover Ratio Statistics
High	Average	Low
0.75	0.52	0.02
(Jun 30 2020)		(Dec 31 2013)

NBIX Company Profile • Back to NBIX Efficiency Comparisons • Compare NBIX Receivables Turnover Ratio to its Competitors

Financial Statements
Neurocrine Biosciences Inc 's Accounts Receivable	$ 887 Millions	Visit NBIX's Balance sheet
Neurocrine Biosciences Inc 's Sales TTM	$ 3,374 Millions	Visit NBIX's Income Statement
Sources of NBIX's Revenues		Visit NBIX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NBIX's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NBIX's Growth Rates	NBIX's Roa	NBIX's Inventory Turnover Ratio	NBIX's Dividend Comparisons
NBIX's Profitability Ratios	NBIX's Roi	NBIX's Asset Turnover Ratio	NBIX's Dividend Growth
NBIX's Valuation Ratios	NBIX's Roe	NBIX's Financial Strength Ratios	NBIX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Irhythm Holdings Inc	10.42	$ 825.702 Millions	$ 79.250 Millions
Immucell Corporation	10.29	$ 29.777 Millions	$ 2.893 Millions
Addus Homecare Corp	10.23	$ 1,475.610 Millions	$ 144.195 Millions
Dariohealth Corp	10.23	$ 21.196 Millions	$ 2.072 Millions
Biodesix Inc	10.21	$ 102.939 Millions	$ 10.081 Millions
Viemed Healthcare Inc	10.18	$ 301.606 Millions	$ 29.637 Millions
Radnet Inc	10.11	$ 2,268.932 Millions	$ 224.447 Millions
Kestra Medical Technologies Ltd	10.00	$ 105.939 Millions	$ 10.590 Millions
United Therapeutics Corporation	9.93	$ 3,154.500 Millions	$ 317.550 Millions
Utah Medical Products Inc	9.88	$ 35.679 Millions	$ 3.612 Millions
Lensar Inc	9.75	$ 60.264 Millions	$ 6.184 Millions
Biolife Solutions Inc	9.67	$ 102.718 Millions	$ 10.626 Millions
Encompass Health Corporation	9.57	$ 6,206.100 Millions	$ 648.325 Millions
The Oncology Institute Inc	9.57	$ 587.244 Millions	$ 61.364 Millions
Alumis inc	9.44	$ 7.398 Millions	$ 0.784 Millions
Enanta Pharmaceuticals Inc	9.29	$ 65.258 Millions	$ 7.027 Millions
Neuronetics Inc	9.24	$ 154.594 Millions	$ 16.732 Millions
Myomo Inc	9.24	$ 44.242 Millions	$ 4.790 Millions
Harmony Biosciences Holdings inc	9.22	$ 960.191 Millions	$ 104.164 Millions
Pavmed Inc	9.16	$ 0.126 Millions	$ 0.014 Millions
Ardent Health Inc	9.16	$ 6,405.940 Millions	$ 699.363 Millions
The Pennant Group Inc	9.15	$ 1,101.710 Millions	$ 120.457 Millions
Lexicon Pharmaceuticals Inc	9.14	$ 41.469 Millions	$ 4.535 Millions
Bioaffinity Technologies Inc	9.11	$ 5.901 Millions	$ 0.648 Millions
Nuvation Bio Inc	9.05	$ 169.551 Millions	$ 18.737 Millions
Sunshine Biopharma Inc	9.03	$ 35.347 Millions	$ 3.916 Millions
Biocryst Pharmaceuticals Inc	9.00	$ 940.613 Millions	$ 104.543 Millions
Biofrontera Inc	8.88	$ 45.956 Millions	$ 5.178 Millions
Novavax inc	8.86	$ 413.796 Millions	$ 46.693 Millions
Grail Inc	8.85	$ 165.263 Millions	$ 18.670 Millions

Date modified: 2026-08-31T07:05:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.